602303-26-4

Basic information

• Product Name: 7-CHLORO-2-IODOTHIENO[3,2-B]PYRIDINE
• Synonyms: 7-CHLORO-2-IODOTHIENO[3,2-B]PYRIDINE;7-chloro-2-iodothieno[3;7-Chloro-2-iodothieno[3,2...;Thieno[3,2-b]pyridine, 7-chloro-2-iodo-
• CAS NO: 602303-26-4
• Molecular Formula: C₇H₃ClINS
• Molecular Weight: 295.53
• Product Categories: CHIRAL CHEMICALS;Pyridines;Heterocycles
• Mol File: 602303-26-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 341.701 ºC at 760 mmHg
• Flash Point: 160.455 ºC
• Appearance: /
• Density: 2.107 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.771
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.18±0.40(Predicted)
• CAS DataBase Reference: 7-CHLORO-2-IODOTHIENO[3,2-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLORO-2-IODOTHIENO[3,2-B]PYRIDINE(602303-26-4)
• EPA Substance Registry System: 7-CHLORO-2-IODOTHIENO[3,2-B]PYRIDINE(602303-26-4)

Safety Data

• Hazardous Substances Data: 602303-26-4(Hazardous Substances Data)

Usage

General Description

7-Chloro-2-iodothieno[3,2-b]pyridine is a chemical compound with the molecular formula C6H3ClIN. It is a heterocyclic compound that contains a thieno[3,2-b]pyridine ring with chlorine and iodine substituents. 7-Chloro-2-iodothieno[3,2-b]pyridine is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable building block for the production of various biologically active compounds. Additionally, it is also used in academic research as a starting material for the development of new chemical reactions and synthesis methods. Overall, 7-Chloro-2-iodothieno[3,2-b]pyridine is a versatile compound with important applications in the pharmaceutical and agrochemical industries as well as in academic research.

InChI:InChI=1/C7H3ClINS/c8-4-1-2-10-5-3-6(9)11-7(4)5/h1-3H

Upstream product

• 69627-03-8 7-chlorothieno[3,2-b]pyridine 

Downstream Products

• 918643-33-1 7-(2-fluoro-4-nitrophenoxy)-2-iodothieno[3,2-b]pyridine 
• 1342835-94-2 1-Cyclopropyl-3-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)urea 
• 225382-63-8 [2-(3-Methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine 
• 875339-66-5 7-chloro-2-tributylstannanyl-thieno[3,2-b]pyridine 
• 946505-64-2 6-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)-1-phenyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one 
• 946505-59-5 2-(benzylamino)-5-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)-3-methylpyrimidin-4(3H)-one 
• 946505-55-1 5-(2,5-difluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one 
• 946505-31-3 5-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)-3-methyl-2-(phenylamino)pyrimidin-4(3H)-one 
• 946505-13-1 2-benzyl-5-(3-fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)phenyl)pyrimidin-4(3H)-one 
• 918643-41-1 3-Fluoro-4-(2-iodothieno[3,2-b]pyridin-7-yloxy)aniline 

Relevant articles and documents

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.